This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove 2029 Remove Drug Development Remove Regulations Related Topics
Pharmaceuticals Marketing Research Drugs Trials Disease Drug Trials Compliance Production Laboratories More Related Topics >
article thumbnail

Inside the Altascientist: Considerations for Safe and Compliant HPAPI Manufacturing

Alta Sciences

MARCH 8, 2024

billion by 2029. Thousands of HPAPIs are currently in development that promise lower dose requirements, enhanced efficacy, improved patient compliance, and fewer side effects. So much so that the HPAPI market is estimated to reach USD 31.5

Compliance 52
Compliance Engineering Regulations Pharmaceuticals 52
article thumbnail

Article FDA Thank You Diagnostics landscape analysis: Key issues and a look ahead at 2024

Agency IQ

FEBRUARY 2, 2024

Diagnostics landscape analysis: Key issues and a look ahead at 2024 Diagnostic regulation in the U.S. Following significant policy proposals in recent years, 2024 is gearing up to be a profoundly impactful year for diagnostics developers and the policymakers who regulate them. is a constantly evolving topic. In the U.S.,

FDA 40
FDA Regulations Laboratories Production 40
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 42,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024